Lumida
/CHRS
⌘K
Coherus Oncology Inc

Coherus Oncology Inc

CHRS
$1.33USD↓-0.75%-0.01 today

MARKET CAP

205.5M

P/E (TTM)

0.8x

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

CHRS remains in a Stage 4 decline with a confirmed LH/LL regime and price below downward-sloping EMAs, supporting a medium-term bearish bias. The recent bounce into the 9/21EMA zone lacks follow-through, making immediate selling unfavorable. We defer execution, trimming into rallies at EMAs and prior resistance areas rather than chasing current extension.

  • ↑Q2 2026 revenue $13.6M (+37% YoY; +15% QoQ) driven by Lactorsi.
  • ↑Cash $105.3M after cutting R&D to $21.4M and SG&A to $21M.
  • ↓Net loss narrowed to $33.3M (-$0.22/share) remains significant.
Full analysis →

Buying

4

institutions

Selling

2

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY12.00 M16.80 M+1.64 M-4.1%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY1.33 M1.86 M+124.16 K-8.6%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUY563.06 K788.28 K+231.36 K+40.6%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL175.01 K245.02 K+-218.03 K-63.1%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY66.07 K95.80 K+12.91 K+12.6%0.00%
MM

Millennium Management LLC

Q2 2026

SELL20.75 K29.05 K+-291.24 K-94.5%0.00%